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Abstract
Background: COPD is characterised by loss of alveolar elastic fibers and by lack of effective
repair. Elastic fibers are assembled at cell surfaces by elastin binding protein (EBP), a molecular
chaperone whose function can be reversibility inhibited by chondroitin sulphate of matrix
proteoglycans such as versican. This study aimed to determine if alveoli of patients with mild to
moderate COPD contained increased amounts of versican and a corresponding decrease in EBP,
and if these changes were correlated with decreases in elastin and FEV1.
Methods: Lung samples were obtained from 26 control (FEV1 ≥ 80% predicted, FEV1/VC >0.7) and
17 COPD patients (FEV1 ≥ 40% – <80% predicted, FEV1/VC ≤ 0.7) who had undergone a lobectomy
for bronchial carcinoma. Samples were processed for histological and immuno-staining. Volume
fractions (Vv) of elastin in alveolar walls and alveolar rims were determined by point counting, and
versican and EBP assessed by grading of staining intensities.
Results: Elastin Vv was positively correlated with FEV1 for both the alveolar walls (r = 0.66, p <
0.001) and rims (r = 0.41, p < 0.01). Versican was negatively correlated with FEV1 in both regions
(r = 0.30 and 0.32 respectively, p < 0.05), with the highest staining intensities found in patients with
the lowest values for FEV1. Conversely, staining intensities for EBP in alveolar walls and rims and
were positively correlated with FEV1 (r = 0.43 and 0.46, p < 0.01).
Conclusion:  Patients with mild to moderate COPD show progressively increased immuno-
staining for versican and correspondingly decreased immuno-staining for EBP, with decreasing
values of FEV1. These findings may explain the lack of repair of elastic fibers in the lungs of patients
with moderate COPD. Removal of versican may offer a strategy for effective repair.
Background
Chronic obstructive pulmonary disease (COPD) is charac-
terised by loss of elastin in the alveolar walls [1-3].
Recently, we reported that in patients with mild to mod-
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erate COPD (GOLD stages 1 and 2) the decreased elastic
fiber content of alveoli and small airways strongly corre-
lates with decreased FEV1 [4], consistent with a central role
for the loss of elastin in the airflow obstruction in COPD.
In COPD, elevated levels of the elastin degrading protein-
ases MMP-2 and MMP-9 have been found in lung tissue
[5,6], alveolar macrophages [7], and sputum of subjects
with COPD [8,9] and may contribute to the loss of elastic
fibers in COPD. There is evidence from animal studies
that repair processes are also activated in the parenchyma
of lungs affected by emphysema, and that synthesis of
extracellular components, including elastin and collagen,
is increased. The elastin, however, is abnormally organ-
ised and distributed, and not laid down in functional net-
works of fibers [10-12].
Recent studies on the assembly of elastic fibers point to an
inhibitory role for the matrix proteoglycans. Assembly of
elastic fibers occurs in the extracellular matrix immedi-
ately adjacent to the cell surface and is mediated by the 67
kD cell surface receptor elastin binding protein (EBP).
EBP, an inactive splice variant of β galactosidase, chapar-
ones tropoelastin through the Golgi and endosomal com-
partments of elastogenic cells to the cell surface where it
delivers tropoelastin to growing fibers [13]. This process is
inhibited by a high concentration of pericellular galactos-
ugars, such as the chondroitin sulphate (CS) chains of the
proteoglycans versican and biglycan. Chondroitin sul-
phate chains bind to EBP and cause premature shedding
of EBP from the cell surface. As a result, tropoelastin is not
presented to the microfibrillar scaffolds and fiber forma-
tion is impaired [14,15].
Versican-mediated inhibition of elastic fiber assembly
may also occur in lung tissues. In lymphangioleiomyoma-
tosis (LAM), thickened alveolar walls and expanded inter-
stitial tissues stain strongly for versican, as well as
biglycan. These proteoglycan-rich regions are notably
devoid of elastic fibers and stain weakly for EBP [16].
Total elastin content of LAM lungs, however, is not
reduced and interstitial regions that have a low content of
proteoglycan stain strongly for EBP and contain bundles
of elastic fibers. These fibers, however, are not arranged in
a network, indicating a problem with functional architec-
ture rather than impairment of synthesis.
These findings raise the possibility that elastic fiber repair
processes in COPD may be inhibited by an increased con-
tent of matrix proteoglycans. In this study, we asked the
questions, do the lungs of patients with mild to moderate
COPD stain more intensely for versican and less intensely
for EBP, and does FEV1 predict those changes?
Materials and methods
The lung tissue used in this study has been described pre-
viously [4]. The study was conducted using archived for-
malin fixed, paraffin embedded tissues from patients who
had one or more lobes resected for bronchial carcinoma.
The specimens were identified using the computerized
records of the Department of Pathology, Green Lane Hos-
pital. The operations were performed between January
1992 and September 1996. Further information, includ-
ing smoking history, past medical history, medication and
preoperative lung function, were obtained from the
patient's hospital notes. The patients were classified as
control subjects or COPD on the basis of their lung func-
tion. The control subjects had FEV1 ≥ 80% predicted and
FEV1/FVC ≥ 0.7. Patients with FEV1 <80% and FEV1/FVC ≤
0.7 were classified as COPD. (For characteristics of sub-
jects who provided archival tissue see Table 1, reference
4.) Patients with a diagnosis of asthma, bronchiectasis or
interstitial lung disease were excluded and there were no
changes seen in the tissue sections from the included sub-
jects to suggest these diagnoses. Samples were obtained
from 26 control and 17 COPD subjects ranging in age
from 58 to 90 and 61 to 84 years respectively. Approval
was obtained from the Auckland Ethics Committee to
conduct the study.
All samples had been fixed in neutral buffered 10% for-
malin and embedded in paraffin. Histological- and
immuno-staining was performed on 4 μm sections
mounted on glass slides. Elastic fibers were visualised by
elastin van Gieson staining as previously described [4],
and versican, and elastin binding protein (EBP) by
immuno-staining with monospecific polyclonal antibod-
ies raised in rabbits. Proteoglycan antibodies (versican
LF99, biglycan LF121 and decorin LF122) were kindly
provided by Dr Larry Fisher, Craniofacial and Skeletal Dis-
ease Branch, National Institutes of Dental Research, NIH,
Bethesda, Maryland. Anti- EBP antibody, raised to the syn-
thetic peptide reflecting the elastin binding domain of the
spliced variant of human β-galactosidase was previously
described by Hinek and colleagues [17].
Deparaffinised sections were hydrated in tris buffered
saline (TBS) for 3 × 5 mins, incubated with 0.03% perox-
idase block for 10 mins, washed in TBS 3 × 5 mins, and
incubated with primary antibodies (versican, biglycan
and decorin at 1:1000, and EBP at 1:500) for 1 hr and 1.5
hr respectively. Following primary incubation, sections
were washed 3 × 5 mins in TBS, incubated for 30 mins in
secondary HRP rabbit polymer, washed 3 × 5 mins in TBS
and stained with DAB chromogen for 6 mins. Sections
were then washed twice in distilled water, counterstained
with Harris' Haematoxylin and differentiated in tap water
for one minute, dehydrated and mounted in hystomount.
Control sections for immuno-staining received identicalRespiratory Research 2008, 9:41 http://respiratory-research.com/content/9/1/41
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treatment, except for incubation for 1 hr in TBS in place of
the primary antibodies.
The volume fraction % (Vv) of elastic fibers was deter-
mined as a percentage of total tissue volume by point
counting using a 100 point grid as described previously
[4]. For each lung sample, 10 random sites were sampled
and mean elastin Vv determined for alveolar wall and
alveolar rim regions separately. The analysis was per-
formed by an investigator (PC) who was blinded to the
patient's lung function. The sections were examined under
a light microscope at 40× magnification linked by a video
camera to a computer screen. The on-screen magnification
was 400×. A 100 point grid (covering 2,500 sq microns)
was overlaid on the computer screen and the volume frac-
tion percent calculated from the number of times a darkly
stained elastic fiber registered as a hit (i.e. fell on the grid).
This was expressed as a percentage of the total number of
times that alveoli walls, alveolar rims registered as a hit on
the grid. For each patient 10 sites were randomly sampled
for alveoli and for alveolar rims. For each patient the
mean number of alveolar tissue points sampled was 420
± 118 (SD) and for alveolar rim regions 520 ± 98 (SD).
Immuno-staining intensities were scored on a scale of 0
(no staining) to 5.0 (intense) under a light microscope
(Olympus U-PMTVC) with half grades (eg 3.5) assigned if
there was indecision in applying a whole integer. Gener-
ally, staining intensities for EBP were less than for versi-
can, but with the most intense assigned a value of 5 so that
the range in intensities could be fully assessed. Assessment
of intensities was carried out under a 20× objective lens
with a minimum of 10 random sites sampled for each
patient. The scorer (PC) was blinded to the patient codes.
For each lung sample, the alveolar walls and alveolar rim
regions were scored separately. To validate the grading
system, versican scores for all subjects were collected from
two independent observers (PC and BB), both blinded to
the patient codes, and the scores compared using Spear-
man's rank correlation coefficient test. The concordance
between the observers was high with rS = 0.857 (p <
0.001).
Data were analysed by Students T test (between groups)
and by least squares linear regression (with FEV1 % pre-
dicted, FEV1 /VC or elastin Vv the independent variable);
p of <0.05 was taken as significant.
Results
Elastin staining
Elastin van Gieson staining (Fig 1a,b) showed reduced
elastic fiber staining in the both alveolar wall and alveolar
Lung sections stained for elastin, versican and elastin binding protein Figure 1
Lung sections stained for elastin, versican and elastin binding protein. Control (upper panels) and COPD (lower pan-
els) lung sections stained for elastin (a,b)(x250), versican (c,d) (x100) and elastin binding protein (EBP) (e,f) (x100). Arrow 
heads indicate elastin and the boxes in a and b indicate alveolar rim regions. Staining patterns demonstrate the reciprocal rela-
tionships between versican and elastin and EBP. Inserts show segments of alveolar wall (× 500). Staining intensity values are 1 
for c and f and 5 for d and e.Respiratory Research 2008, 9:41 http://respiratory-research.com/content/9/1/41
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rim regions of COPD lungs compared with control lungs.
As reported previously [4] the mean alveolar wall elastin
Vv in COPD lungs (18.6% ± SD 5.5) was significantly
lower (p < 0.001) than in control lungs (32.8% ± 7.6). The
elastin content of the alveolar rims, which was higher than
in the alveolar walls, was also reduced (Figure 1a,b), but
to a lesser extent. The mean elastin Vv in the COPD group
(31.5% ± 6.3) was significantly lower (p < 0.002) than in
controls (39.0% ± 7.9). The higher Vv of elastin in the
alveolar rims of controls, compared with the alveolar
walls of controls, is consistent with the visual concentra-
tion of circumferentially arranged elastic fibers around the
rims of alveoli.
In our previous study [4] we also found that a decrease in
FEV1 was accompanied by a decrease in elastin Vv (Figure
2a,) for alveolar wall (r = 0.66, p < 0.001). We report here
a similar relationship between FEV1 and Vv of elastin in
alveolar rims (Figure 2b) (r = <0.41, p < 0.01). Similar cor-
relations were found for FEV1/VC and elastin Vv (data not
shown).
Versican staining
COPD lung samples stained more strongly for versican
than control lung samples (Figure 1c,d). Mean staining
intensity scores for alveolar wall of COPD samples were
significantly (p < 0.002) higher than control samples (3.5
± SD 1.5 vs 2.1 ± 1.3), as were scores for the alveolar rim
regions (3.6 ± 1.5 vs 2.1 ± 1.3; p < 0.001). The stronger
staining for versican and the emphysematous nature of
COPD lung compared with control lung was evident on
low power images of lung parenchyma (Figure 3a,b).
Versican staining intensities for both alveolar wall and
alveolar rim were significantly and negatively correlated
with FEV1 (r = 0.30 and r = 0.32 respectively, p < 0.05) (Fig
4a,b), with the highest staining intensities occurring in
COPD patients with FEV1 less than 60% of predicted. Sim-
ilarly, versican intensity was negatively correlated with
elastin Vv in alveolar rim regions (r = 0.32, p < 0.05) (Fig-
ure 5b). For alveolar wall this correlation was again nega-
tive but did not reach significance (r = 0.20) (Figure 5a).
Reciprocal relationship between versican and elastin binding  protein Figure 3
Reciprocal relationship between versican and elastin 
binding protein. Low power images of lung sections from a 
control patient (a,c) and a COPD patient (b,d) immunos-
tained (using DAB chromogen) for versican and EBP. For 
each patient the images were taken from the same regions. 
Staining patterns show the reciprocal relationship between 
versican and EBP and the COPD lung shows the typical 
emphysematous structure. Scale bars = 400 μm
a
cd
b
Relationship between elastin and FEV1 Figure 2
Relationship between elastin and FEV1. Relationship 
between elastic fiber volume fraction % of alveolar wall (a) 
and alveolar rims (b) and FEV1% in control (closed circles) 
and COPD (open circles) patients. (Data for (a) from [4] 
with permission.)
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EBP staining
Immuno-staining of alveolar walls with anti-EBP anti-
body was significantly (p < 0.003) more intense in control
lungs (mean 3.7 ± 1.3) than in COPD lungs (mean 2.4 ±
1.3). EBP intensity in the alveolar rims of controls (3.9 ±
1.1) was similarly higher (p < 0.001) than in COPD
patients (2.8 ± 1.3). As for elastin volume fractions, EBP
showed a reciprocal pattern to versican; intensities for
both regions were significantly (p < 0.01) and positively
correlated with FEV1 (r = 0.43 alveolar wall, r = 0.46 for
rims) (Figure 6a,b). This reciprocal relationship was evi-
dent in low power images of control and COPD lung (Fig-
ure 3c,d) as well as in higher power images (Figure 1e,f).
EBP similarly showed a positive relationship with elastin
Vv for alveolar wall (r = 0.40, p < 0.01), and a non-signif-
icant trend for the alveolar rims (Figure 7a,b).
Immuno-staining was also undertaken for two other
matrix proteoglycans, biglycan and decorin. Although
present at low levels in the walls and rims of alveoli, stain-
ing intensities were similar in both control (biglycan 1.0
± 0.6, decorin 2.0 ± 0.8) and COPD patients (biglycan 1.2
± 0.9, decorin 2.1 ± 1.3) and neither proteoglycan showed
any relationship with FEV1 or with elastin Vv.
Discussion
A reciprocal relationship between versican and elastin and
EBP has been previously demonstrated for vascular [18]
and dermal tissues [19], and also for the rare lung condi-
tion lymphangioleiomyomatosis [16]. The findings of
this present study show that the same relationship occurs
in lung parenchyma of patients with mild to moderate
COPD, and may explain, at least in part, why restoration
of a functional elastic fiber network does not occur in
lungs affected by COPD, despite a demonstrated capacity
of emphysematous lung tissue to re-synthesise elastin and
other matrix components.
In proposing a functional relationship between versican
content and deposition of elastic fibers it is recognised
that the immuno-staining approach used here does have
limitations. For the samples available it was not possible
Relationship between versican and elastin Figure 5
Relationship between versican and elastin. Relationship 
between versican immuno-staining intensities for alveolar 
wall (a) and alveolar rims (b) and elastic fiber volume fraction 
% in control (closed circles) and COPD (open circles) 
patients.
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Relationship between versican and FEV1 Figure 4
Relationship between versican and FEV1. Relationship 
between versican immuno-staining intensities for alveolar 
wall (a) and alveolar rims (b) and FEV1% in control (closed 
circles) and COPD (open circles) patients.
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to determine protein levels for versican and EBP and an
assumption is made that staining intensities reflect con-
tent. Unmasking of epitopes with progression of COPD,
however, could result in increased staining intensities
without an increase in versican, although other studies,
for example on human vessels, have shown a good corre-
lation between immuno-staining intensities, precursor
incorporation, and extracted amounts of proteoglycan
[20,21]. Additionally, the versican antibody recognises all
forms of versican, including the chainless variant V3, and
it could be possible that V3 is upregulated in COPD.
Other studies however, indicate that this is highly unlikely
as V3, when present, is expressed at low levels [22], and
attempts to understand possible functions have been
through overexpression studies [18,19,35]. Further, we
also recognise that our method of quantifying the amount
of elastin does not provide a measure of the quality of the
elastic fibers. The confocal images, however, indicate sig-
nificant changes to the elastic fiber network that likely
affect alveolar function.
Several experimental studies, reviewed by Snider et al
[10], and by Chambers and Laurent [12] have reported
that matrix proteins, including elastin and collagen, are
re-synthesised in emphysematous lungs in animal models
but that deposition of these components does not result
in restoration of physiological function. Morris et al [23]
showed that an elastase insult to hamster lungs resulted in
new deposits of elastin close to cell surfaces, but a failure
to form fibers. Osman et al [24] similarly demonstrated
re-synthesis of elastin through measurement of incorpo-
rated 14C into desmosine and isodesmosine in a hamster
model and additionally showed that re-synthesis was
decreased by cigarette smoke which inhibited lysyl oxi-
dase activity. Similarly, investigations on human emphy-
sematous lungs have reported re-synthesis of matrix
proteins, but with changed distribution patterns of colla-
gens and elastin. An early study by Belton et al [25] and a
later study by Fukuda et al [26] suggested that new elastin
deposits may have been formed but that they were abnor-
mal and included clumping of fibers in the free edges or
rims of alveolar walls.
Relationship between elastin binding protein and elastin Figure 7
Relationship between elastin binding protein and 
elastin. Relationship between EBP immuno-staining intensi-
ties for alveolar wall (a) and alveolar rims (b) and elastic fiber 
volume fraction % in control (closed circles) and COPD 
(open circles) patients.
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Relationship between elastin binding protein and FEV1 Figure 6
Relationship between elastin binding protein and 
FEV1. Relationship between EBP immuno-staining intensities 
for alveolar wall (a) and alveolar rims (b) and FEV1% in con-
trol (closed circles) and COPD (open circles) patients.
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Recent evidence points to versican as an important inhib-
itor of elastic fiber formation and our findings of
increased versican in COPD and decreased EBP provide
for a mechanism. It has been previously established that
tropoelastin present in endosomal and Golgi compart-
ments is escorted by the 67-kDa EBP which protects this
non-glycosylated and hydrophobic precursor of elastin
from premature intracellular self-aggregation and associa-
tion with serine proteinases [27]. Of particular impor-
tance was the observation that 67-kDa EBP also has a
separate galactolectin domain and that binding of galac-
tosugars to this site induces conformational changes in
the EBP molecule, resulting in its dissociation from tro-
poelastin [28,29,14]. This led to the paradigm, that the
release of newly secreted tropoelastin molecules from
their EBP transporters, is highly coordinated and occurs
on the cell surface, following the interaction between EBP
and galactosugar moieties, presumably those protruding
from carbohydrate chains of glycoproteins forming the
microfibrillar scaffold of new elastic fibers [30,31].
On the other hand, it has been also established that such
coordinated assembly of tropoelastin into elastic fibers
can be disrupted by pericellular accumulation of galacto-
sugar-bearing moieties, such as chondroitin sulfate or der-
matan sulfate, which induce premature shedding of the
EBP from the cell surface and release of tropoelastin, away
from microfibrilar acceptors [14,17,32-34]. Thus, high
levels of versican in the pericellular coat could inhibit
fiber assembly even though there may be adequate syn-
thesis of both tropoelastin and EBP. Interestingly, under
normal circumstances, the efficiency of elastogenesis does
not generally exceed 40–60% (unpublished data of AH)
with proportionately more tropoelastin than EBP. The
recycling of EBP likely mitigates against this imbalance,
but displacement of EBP by versican would affect recy-
cling. We do not know the minimal concentration of ver-
sican required to completely inhibit elastic fiber assembly.
Evidence suggests that impaired elastic fiber assembly,
caused by pericellular accumulation of galactosugar-con-
taining moieties could be reversible. Recently, it has been
demonstrated, for vascular smooth muscle cells, that tro-
poelastin synthesis and elastic fiber assembly can be
enhanced by reducing the amount of versican in the cell
coat. This has been achieved by two methods, by overex-
pressing the glycosaminoglycan deficient variant of versi-
can, V3 [35], which is believed to displace the larger
versican variant V1 from its attachment to hyaluronan,
and by reducing all versican variants at source by overex-
pressing a versican antisense sequence [18]. In vivo,
neointima formed from smooth muscle cells overexpress-
ing either V3 or versican antisense, is enriched in elastin.
Significantly this elastin is organised as parallel arrays of
circumferentially arranged fibers and lamellae that resem-
ble those in developing media, indicating that a func-
tional arrangement can be achieved in vivo by
manipulating levels of versican. In this model, the level of
EBP in the neointima was reciprocally related to the level
of versican, as found for this present study of COPD lungs.
Overexpression of V3, leading to decreased cell-associated
chondroitin sulphate, has also been used successfully to
restore elastic fiber formation in cultures of skin fibrob-
lasts from Costello Syndrome patients who have a defi-
ciency of elastic fibers due to over production of CS
proteoglycans [19].
There are reports of increased glycosaminoglycan content
in emphysematous lungs [36,37] although with dermatan
rather than chondroitin sulphate being increased. In
severe emphysema, the interstitial proteoglycans decorin
and biglycan are reported to be decreased [38] but this
was not found in this present study which examined
patients with much milder emphysema. Increased versi-
can has been reported for various lung diseases including
fibrosis [39], granulomatous diseases [40], asthma
[41,42], and LAM [16]. In the latter the total amount of
elastin was increased, consistent with re-synthesis, but the
fibers were often aggregated into bundles between elastin-
free myxoid regions rich in versican and biglycan. In a
recent study it has been demonstrated in developing lung
that versican levels are initially raised and correlated with
high tissue volume, and as development and alveolariza-
tion proceeds the levels of versican decrease, accompanied
by a decrease in hydrated tissue volume. Significantly this
decrease in versican precedes the rise in elastin content
[43].
The findings from this present study raise a testable
hypothesis, namely that repair of the elastin network in
lung parenchyma, and restoration of physiological func-
tion, might be achievable, at least in mild COPD, by
reducing the versican content of alveolar wall. Lowering of
versican in such lungs might be particularly effective as
alveoli would still be subjected to the mechanical move-
ments of ventilation that likely have a role in determining
the pattern and placement of elastic fibers during repair.
The elastic fibers in the alveolar rims may be particularly
important. These fibers are thicker and more prominent
than those forming the elastic fiber network in the alveo-
lar wall [44] and are important developmentally in defin-
ing the septa between alveoli [45]. Restoration of fibers in
this region may be crucial to lung function. Moreover,
more efficient assembly of the secreted tropoelastin may
lead to a decrease in the level of free tropoelastin-derived
peptides that are capable of inducing production of elas-
tolytic MMP's [46]. Notably, in our study, the loss of elas-
tin in the alveolar rims with decreasing FEV1 was less than
for alveolar wall (Fig 2), possibly indicative of repair and
maintenance despite degradative processes. Interestingly,Respiratory Research 2008, 9:41 http://respiratory-research.com/content/9/1/41
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the synthesis of elastin is greater in this region after an
elastase challenge [47].
The loss of alveolar structure in more severe COPD clearly
presents a much greater challenge for effective remodel-
ling and the argument for proteoglycan-modulated repair
that is proposed here may only apply to mild COPD
where the architecture of the lung is not greatly changed.
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